With a diverse platform of therapies and a broad and extensive IP portfolio, BioTime and its affiliates have a high probability of success. Long term, deep pocketed, shareholder support is key for a developmental stage biotech's survival and success.
http://ift.tt/1yV9gIh
http://ift.tt/1yV9gIh
No comments:
Post a Comment